Compare NTLA & CEPU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTLA | CEPU |
|---|---|---|
| Founded | 2014 | 1989 |
| Country | United States | Argentina |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.1B |
| IPO Year | 2016 | 2017 |
| Metric | NTLA | CEPU |
|---|---|---|
| Price | $12.72 | $14.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 1 |
| Target Price | ★ $20.02 | $17.50 |
| AVG Volume (30 Days) | ★ 3.1M | 225.7K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,671,000.00 | N/A |
| Revenue This Year | N/A | $10.11 |
| Revenue Next Year | $62.75 | N/A |
| P/E Ratio | ★ N/A | $12.24 |
| Revenue Growth | ★ 16.92 | N/A |
| 52 Week Low | $7.95 | $7.43 |
| 52 Week High | $28.24 | $18.50 |
| Indicator | NTLA | CEPU |
|---|---|---|
| Relative Strength Index (RSI) | 51.41 | 54.64 |
| Support Level | $12.55 | $13.95 |
| Resistance Level | $13.88 | $15.65 |
| Average True Range (ATR) | 0.66 | 0.49 |
| MACD | 0.06 | 0.16 |
| Stochastic Oscillator | 53.28 | 71.13 |
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Central Puerto SA is a power generation company. It is mainly engaged in electric power generation and commercialization. The company is also involved in the natural gas distribution public sector service in the Cuyo and Centro regions in Argentina. The Group has four reporting segments which includes electric power generation from conventional sources, electric power generation from renewable sources, natural gas transport and distribution, and forest activity. The company derives maximum revenue from Electric Power Generation from conventional sources segment.